CAMBRIDGE - FEBRUARY 28: Moderna in Cambridge, MA is pictured on Feb. 28, 2020. Moderna has developed the first experimental coronavirus medicine, but an approved treatment is more than a year away. (Photo by David L. Ryan/The Boston Globe via Getty Images)
Moderna’s investigational vaccine for the novel coronavirus has been cleared by the US Food and Drug Administration to proceed to phase two of a study, the company said Thursday in a press release.
The next phase of the trial is expected to begin shortly, it said.
The vaccine, mRNA-1273, was the first US vaccine to start clinical trials in the United States. Moderna said it is finalizing protocol for a phase 3 study which is expected to begin in early summer.
